| Authors: |
Fitzgerald L; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City.; George E. Wahlen Veterans Affairs Medical Center, Salt Lake City, UT., Ghosh S; Janssen Scientific Affairs, a Johnson & Johnson Company, Horsham, PA., Khan W; Janssen Scientific Affairs, a Johnson & Johnson Company, Horsham, PA., Bokun A; Janssen Scientific Affairs, a Johnson & Johnson Company, Horsham, PA., Lax A; Analysis Group, Inc., Boston, MA., Mu F; Analysis Group, Inc., Boston, MA., Cook EE; Analysis Group, Inc., Boston, MA., Chen J; Analysis Group, Inc., Boston, MA., Chen G; Analysis Group, Inc., Boston, MA., Wu E; Analysis Group, Inc., Boston, MA., Lin Y; Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA.; Southeast Louisiana Veterans Health Care System, New Orleans., Shi L; Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA.; Southeast Louisiana Veterans Health Care System, New Orleans., Qureshi ZP; Janssen Scientific Affairs, a Johnson & Johnson Company, Horsham, PA., Graf SA; Division of Hematology/Oncology, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Hospital and Specialty Medicine, Veterans Affairs Puget Sound Health Care System, Seattle, WA. |
